In 2023, the liver cancer drugs market was valued at $2.67 billion. By 2032, it is expected to grow significantly, reaching $9.94 billion with an impressive compound annual growth rate (CAGR) of 14.2% from 2024 to 2032.
Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5146
The Central Drug Research Institute (CDRI), India, has made significant progress in liver cancer research through a collaborative study. The research focuses on the metabolic changes occurring in cells that could play a key role in preventing hepatocellular carcinoma (HCC), the most common type of liver cancer.
Conducted in partnership with CIMAP, CBMR, and CSIR-CDRI, the study highlights how cancer cells undergo a shift in metabolic programming. These alterations could pave the way for improved diagnostic and preventive strategies.
Led by Dr. Madhav Nilakanth Mugale of CSIR-CDRI, the research used an animal model to replicate the progression of HCC in humans. It identified critical changes associated with disease advancement, such as decreased body mass, elevated serum enzyme levels, and alterations in liver structure.
Published in the prestigious Elsevier journal, this study opens the door to developing targeted therapies based on metabolic reprogramming, offering hope for more effective treatments for liver cancer.
Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions: https://www.towardshealthcare.com/table-of-content/liver-cancer-drugs-market-sizing
Access exclusive insight now @ https://www.towardshealthcare.com/price/5146
We’ve prepared a service to support you. Please feel free to contact us at sales@towardshealthcare.com
Web: https://www.towardshealthcare.com
Visit Dental Specifics: https://www.towardsdental.com
Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription
For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare
Kedrion Biopharma has announced that its human coagulation factor X concentrate, COAGADEX®, has been granted orphan drug designation by the… Read More
enecard PBF, a pioneer in pharmacy benefit facilitation, has announced a strategic partnership with DecisionRX, Inc., a leader in medication… Read More
In a high-stakes biotech industry where drug development can span over a decade, four small but determined biotech companies are… Read More
cell-free DNA and precision medicine, has officially announced the launch of the TEODOR trial (ABCSG 61), a groundbreaking phase 2,… Read More
The global interventional radiology market is witnessing rapid expansion, driven by advancements in minimally invasive procedures, rising demand for diagnostic… Read More
The global physical therapy market is valued at USD 28.06 billion in 2024, growing to USD 29.18 billion in 2025… Read More